<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531581</url>
  </required_header>
  <id_info>
    <org_study_id>14-AOI-11</org_study_id>
    <nct_id>NCT02531581</nct_id>
  </id_info>
  <brief_title>Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive</brief_title>
  <official_title>Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary embolism (PE) is a serious disease with frequent intra hospital mortality remains&#xD;
      high. If anticoagulation is perfectly codified, the remainder of the initial management has&#xD;
      been less studied.&#xD;
&#xD;
      In particular, the &quot;conditioning&quot; Initial often involves systematic plasma volume of 250 to&#xD;
      500 cc, by analogy to other situations. But this treatment option is not based on factual&#xD;
      data. In the right ventricular dysfunction that often accompany severe EP, volume expansion&#xD;
      may instead be harmful, according to the law of Frank Starling. A retrospective study has&#xD;
      recently shown a benefit of diuretic therapy in patients hospitalized for severe normotensive&#xD;
      EP.&#xD;
&#xD;
      The proposed study is interventional, prospective, multicenter, randomized, require to&#xD;
      include 60 patients.&#xD;
&#xD;
      The main objective of the study is the comparison of the troponin normalization period Ic&#xD;
      (biomarker of right ventricular dysfunction) in patients hospitalized in the initial phase of&#xD;
      a serious normotensive EP, between the 2 groups diuretic and filling Vascular.&#xD;
&#xD;
      The primary endpoint is the time in hours standardization of troponin Ic.&#xD;
&#xD;
      The secondary endpoints will be:&#xD;
&#xD;
        -  the period of normalization of Brain Natriuretic Peptide (BNP)&#xD;
&#xD;
        -  changes in echocardiographic parameters of right ventricular dysfunction&#xD;
&#xD;
        -  a composite endpoint: cardiovascular death / cardiogenic shock / use of amines / use of&#xD;
           thrombolysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:&#xD;
&#xD;
      Compared with the time of normalization of cTnI (biomarker of right ventricular dysfunction)&#xD;
      in hospitalized patients in the initial phase of a serious EP normotensive between the 2&#xD;
      groups diuretic and vascular filling&#xD;
&#xD;
      PRINCIPAL INCLUSION CRITERIA&#xD;
&#xD;
        -  older than 18 Patient&#xD;
&#xD;
        -  Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by a&#xD;
           chest CT)&#xD;
&#xD;
      The serious nature without hypotension is defined by the presence of:&#xD;
&#xD;
        -  From biological criteria: troponin and / or BNP positive AND&#xD;
&#xD;
        -  In sonographic criteria: dilated right ventricle defined by echocardiography right over&#xD;
           left ventricle ratio (VG)&gt; 0.9 in apical 4- chamber or 0.7 in large parasternal axis and&#xD;
           right ventricular systolic dysfunction (TAPSE &lt;16 mm and S 'pulsed TDI tricuspid &lt;10 cm&#xD;
           / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial Pressure with&#xD;
           systolic (PAPs)&gt; 35 mmHg or paradoxical septum&#xD;
&#xD;
             -  Informed consent signed&#xD;
&#xD;
             -  Affiliation to social security&#xD;
&#xD;
      PRINCIPAL EXCLUSION CRITERIA&#xD;
&#xD;
        -  Thrombolysis before inclusion&#xD;
&#xD;
        -  State of cardiogenic shock defined as systolic BP &lt;90 mmHg or a drop of&gt; 40 mmHg in&#xD;
           systolic BP for&gt; 15 minutes&#xD;
&#xD;
        -  severe chronic renal impairment defined by clearance &lt;30 ml / min.&#xD;
&#xD;
        -  pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier:&#xD;
           cthC5Fc14NkHBXHkFCiTvGcJ8a8= Page 15/26 women of childbearing age and the results will&#xD;
           be communicated to the patient by a doctor of his choice)&#xD;
&#xD;
        -  Most People under guardianship&#xD;
&#xD;
        -  hospitalized without their consent and not protected by law No&#xD;
&#xD;
        -  Private person of liberty&#xD;
&#xD;
        -  Residence time of more than 24 hours in another department after the positive diagnosis&#xD;
           of pulmonary embolism&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 23, 2015</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">April 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time normalization hours Troponin Ic.</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 12 hours</time_frame>
    <description>This is a direct assay on peripheral venous sampling, easy to collect, accurate and reproducible, made routines in biochemistry laboratories CHU Nice and Antibes CH. Assay kits are the same at the University Hospital of Nice and Antibes CH (BECKMANTM kit). The threshold of positivity of troponin is 0.07 ng / mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Furosémide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output &lt;500 cc / 24 at the 4th hour.&#xD;
Establishment of an infusion G5 500cc% in &quot;vein custody.&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 9% isotonic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an &quot;empirical&quot; in severe EP and this group is therefore the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output &lt;500cc</description>
    <arm_group_label>Furosémide</arm_group_label>
    <other_name>diuretic vascular filling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 9% isotonic</intervention_name>
    <description>normal saline 500 cc / 4 hours and 1 L / 24 hours</description>
    <arm_group_label>NaCl 9% isotonic</arm_group_label>
    <other_name>fluid replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by&#xD;
             a chest CT)&#xD;
&#xD;
        The serious nature without hypotension is defined by the presence of:&#xD;
&#xD;
          -  From biological criteria: troponin and / or BNP positive AND&#xD;
&#xD;
          -  In sonographic criteria: dilated right ventricle defined by echocardiography right&#xD;
             over left ventricle ratio (VG)&gt; 0.9 in apical 4- chamber or 0.7 in large parasternal&#xD;
             axis and right ventricular systolic dysfunction (TAPSE &lt;16 mm and S 'pulsed TDI&#xD;
             tricuspid &lt;10 cm / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial&#xD;
             Pressure with systolic (PAPs)&gt; 35 mmHg or paradoxical septum&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thrombolysis before inclusion&#xD;
&#xD;
          -  State of cardiogenic shock defined as systolic BP &lt;90 mmHg or a drop of&gt; 40 mmHg in&#xD;
             systolic BP for&gt; 15 minutes&#xD;
&#xD;
          -  severe chronic renal impairment defined by clearance &lt;30 ml / min.&#xD;
&#xD;
          -  pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier:&#xD;
             cthC5Fc14NkHBXHkFCiTvGcJ8a8=&#xD;
&#xD;
          -  women of childbearing age and the results will be communicated to the patient by a&#xD;
             doctor of his choice)&#xD;
&#xD;
          -  Most People under guardianship&#xD;
&#xD;
          -  hospitalized without their consent and not protected by law No&#xD;
&#xD;
          -  Private person of liberty&#xD;
&#xD;
          -  Residence time of more than 24 hours in another&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emile FERRARI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

